ImmusanT Inc., a Cambridge, Mass.-based developer of an immunotherapy for Celiac Disease, raised $12m in Series B financing.
Vatera Healthcare Partners LLC made the investment.
Led by Leslie Williams, president and CEO, ImmusanT develops Nexvax2, a disease-modifying immunotherapy designed to enable patients with celiac disease to have a diet containing gluten by tolerizing, or reprogramming, their immune system to tolerate gluten. Recently, ImmusanT completed two Phase 1b studies of Nexvax2 and achieved their objective of demonstrating safety, tolerability and relevant bioactivity.
The results have informed the design of Phase 2 studies, which will commence in early 2015 and the company intends to use the funds to advance development of it.